Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare
B of A Securities cut the price target for DigitalOcean Holdings, Inc. (NYSE: DOCN) from $47 to $25. B of A Securities analyst Wamsi Mohan downgraded the stock from Buy to Underperform. DigitalOcean shares fell 6% to $24.98 in pre-market trading.
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said he is staying long on JPMorgan Chase & Co. (NYSE: JPM), adding that the stock